Federation des caisses Desjardins du Quebec’s Sage Therapeutics SAGE Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100	Closed	-$2.06K	–	2438
2023 Q3	$2.06K	Hold	100	–	–	﹤0.01%	2062
2023 Q2	$4.7K	Hold	100	–	–	﹤0.01%	1927
2023 Q1	$4.2K	Buy	+100	New	+$4.3K	﹤0.01%	1953
2020 Q1	–	Sell	-400	Closed	-$28.9K	–	2343
2019 Q4	$28.9K	Buy	+400	New	+$49.2K	﹤0.01%	1648

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's SAGE Position: Q4 2023 in Review

Federation des caisses Desjardins du Quebec sold out of Sage Therapeutics (SAGE) in Q4 2023, closing a stake of 100 shares — an estimated $2.06K sold.

Federation des caisses Desjardins du Quebec first reported a position in SAGE in Q4 2019 and held it in 4 quarters. The position peaked at $28.9K in Q4 2019. 200 funds tracked by Wall St. Rank hold SAGE as of Q4 2023.

Federation des caisses Desjardins du Quebec reported no remaining Sage Therapeutics position as of Q4 2023 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 100 Sage Therapeutics shares in Q4 2023, an estimated $2.06K.
Federation des caisses Desjardins du Quebec first reported a position in Sage Therapeutics in Q4 2019 and held it in 4 quarters.
Federation des caisses Desjardins du Quebec's Sage Therapeutics position peaked at $28.9K in Q4 2019.
200 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2023.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q4 2023, filed 15 Aug 2024.